Table 4.
Risk factor for cumulative complete remission rate of vulvar Paget’s disease.
| Univariate |
Multivariate |
|||||
|---|---|---|---|---|---|---|
| No. | 6 M (%) | HR (95% CI) | p-Value | HR (95% CI) | p-Value | |
| Year of publication | <0.01 | 0.02 | ||||
| <2011 | 15 | 100% | 1 | 1 | ||
| ≥ 2011 | 48 | 60.6% | 0.30 (0.15–58) | 0.30 (0.14–0.65) | ||
| Area of publication | 0.086 | 0.16 | ||||
| Non-Europe | 21 | 66.5% | 1 | 1 | ||
| Europe | 42 | 73.6% | 1.63 (0.89–3.01) | 1.81 (0.79–4.13) | ||
| Age (years) | 0.90 | 0.41 | ||||
| <70 | 30 | 78.7% | 1 | 1 | ||
| ≥ 70 | 27 | 69.1% | 1.04 (0.55–1.95) | 0.75 (0.38–1.49) | ||
| Disease type | 0.32 | 0.48 | ||||
| Primary | 31 | 74.2% | 1 | 1 | ||
| Recurrence | 32 | 68.9% | 0.75 (0.42–1.37) | 0.76 (0.34–1.66) | ||
| Initial IQ treatment frequency | 0.011 | 0.48 | ||||
| 1–2/week | 9 | 71.9% | 1 | 1 | ||
| 3–4/week | 43 | 65.6% | 0.72 (0.27–1.93) | 0.67 (0.07–6.68) | ||
| 5–7/week | 11 | 90.9% | 1.88 (0.62–5.68) | 1.09 (0.11–11.06) | ||
| Final IQ treatment frequencya | 0.79 | 0.88 | ||||
| 1–2/week | 11 | 62.6% | 1 | 1 | ||
| 3–7/week | 52 | 72.4% | 1.12 (0.45–2.72) | 1.18 (0.14–9.86) | ||
| Reduction of IQ treatment frequency | 0.15 | |||||
| No | 53 | 70.1% | 1 | |||
| Yes | 10 | 80.0% | 1.64 (0.79–3.41) | |||
Log-rank test for univariate analysis and Cox proportional hazard regression test for multivariate analysis. Abbreviations: IQ, imiquimod; 6 M (%), 6-month cumulative complete response rate; HR, hazard ratio: and CI, confidence interval.
a
Cases 3–4/week and 5–7/week were grouped together due to small number for 5–7/week.